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66 The Journal of Thoracic and CardiovObjective: Pediatric mitral valve anomalies present complex management chal-
lenges to the surgeon, who may have to choose between valve replacement or repair.
We review our 18 years of experience to establish the long-term outcomes of
pediatric mitral repair.
Methods: Forty-five children (22 boys) with mitral valve anomalies were studied.
Mitral reconstruction was performed in all cases at the first instance. The median age
at operation was 2.16 years with 18 (40%) younger than 1 year. Patients were
divided into two groups: group 1, isolated (mitral anomaly with or without atrial
septal defect or patent ductus arteriosus), contained 30 patients (66.6%), and group
2, complex (mitral anomaly with concurrent intracardiac disease), contained 15
patients (33.3%).
Results: In-hospital (30-day) mortality in group 1 was 3.3% (1/30); overall in-
hospital mortality was 11.1%. Group 2 had a significantly higher in-hospital death
rate of 26.6% (4/15; P  .05). There was 1 late death, that of a child who required
reoperation. The median follow-up was 5.08 years (range 1-211 months). The
15-year survival in group 1 was 93%, versus 73% in group 2. Seven patients
required 9 revision surgical procedures. Two mitral valve replacements were re-
quired at reoperation. The 15-year freedom from reoperation was 81.7%. There were
no thromboembolic events. The event-free rate at 15 years was 73.5%.
Conclusion: This series compares favorably with others, with 74% to 85% survival
and 66% to 85.7% freedom from reoperation reported with valve replacement.
Patients with significant associated congenital cardiac abnormalities are at a higher
risk of early death after mitral reconstructive surgery.
Since the early 1980s, we have adopted an aggressive approach to repairingmitral valve anomalies in children.1 These anomalies present complex man-agement challenges for the surgeon. Not only must the mitral disease be
addressed, there are frequently associated congenital abnormalities also requiring
reconstruction.2 Mitral valve disease is most commonly seen in the setting of a
partial or complete atrioventricular septal defect (AVSD), multiple left-sided ob-
structive lesions, or isolated mitral valve dysplasia. In managing the mitral pathol-
ogy, the surgeon may have an opportunity to choose between mitral valve replace-
ment and repair. Reconstruction and retention of the native mitral valve and
subvalvular apparatus offers distinct advantages. In comparison with valve replace-
ment, mitral reconstruction conserves the subvalvular apparatus and ventricular
geometry, preserving left ventricular function and resulting in long-term survival
benefits.3 Mechanical valve use in this age group is significantly challenged by
patient-prosthesis size mismatch, which is further complicated as the child grows.
Mitral repair also reduces the risk of thromboembolism and avoids the need for
anticoagulation, which is particularly difficult to manage in the pediatric population.
ascular Surgery ● July 2005
Wood et al Surgery for Congenital Heart Disease
CH
DSeveral groups have reported excellent results with mitral
valve repair.1,4-11 Mitral valve abnormalities in the pediatric
population are rare, and so there is comparatively small and
limited experience with mitral valve repair at each institu-
tion. We reviewed a single-operator (A.W.) experience to
evaluate whether an aggressive advocacy of repair is justi-
fied by calculating survival and freedom from reoperation
and identifying the predictors of adverse outcomes in this
group of patients.
Patients and Methods
Patients
A retrospective review was performed of all children considered
for mitral valve surgery from January 1, 1986, to December 31,
2003. All procedures were performed by a single operator at this
institution, which is the sole provider of national pediatric cardio-
thoracic services. Mitral reconstruction was performed in all cases
in the first instance. Records of 45 children (22 boys and 23 girls)
with mitral valve anomalies were identified. There was 1 case of
acquired mitral incompetence after cardiac catheterization. The
other patients had congenital mitral valve anomalies and concor-
dant atrioventricular and ventricular arterial connection. Cases of
primary correction of total or partial atrioventricular canal defect
and univentricular hearts were excluded. Data were obtained from
medical records and, where these were inadequate regarding fol-
low-up, by contact with the patient’s general practitioner or family.
The median age at operation was 2.16 years (range 2 months to
14.17 years), with 18 (40%) younger than 1 year. The median
weight at operation was 11.5 kg (range 1.5-55.2 kg). Pulmonary
hypertension was moderate (mean 35-45 mm Hg) in 7 cases
(15.5%) and severe (mean 45 mm Hg) in 10 cases (22.2%).
Mitral valve reconstruction was possible in all cases reviewed.
Complete follow-up was obtained in all but 1 case, that of a female
patient emigrated with her family after 9 years of follow-up. She
had been well to that point. Of note, 1 male patient committed
suicide 13 years after surgery. He had been well before that and is
not included as a cardiac-related late death. The median follow-up
was 5.08 years (range 1 month to 17.6 years).
Mitral Pathology
Mitral pathology was classified according to the Carpentier patho-
physiologic classification (Table 1).12 Mitral stenosis was the
dominant lesion in 15 children, and incompetence was dominant in
30. The most common type of mitral valve malformations resulting
in incompetence were anterior leaflet cleft (type I) in 13 patients
(43.3%) and annular dilatation (type I) in 11 patients (36.6%).
Multiple left heart obstructions (Shone anomaly) involving the
mitral valve were found in 1 patient. Seven patients (15.5%)
required repair after AVSD correction. All in this group had
undergone closure of the cleft at primary AVSD repair, which had
been performed within the study era. Patients were divided into
two groups: group 1, isolated (mitral anomaly with or without
atrial septal defect or patent ductus arteriosus), consisted of 30
patients (66.6%), and group 2, complex (mitral anomaly with
intracardiac disease or left ventricular outflow tract obstruction
[LVOTO]), consisted of 15 patients (33.3%). In the complex
group, 8 patients underwent simultaneous repair of ventricular
The Journal of Thoracseptal defect (VSD), and LVOTO was simultaneously addressed in
5, with a subaortic membrane resection in 2 and aortic commis-
surotomy in 3. One of the 7 patients with previous AVSD repairs
had a subaortic stenosis and was placed in group 2. There were 2
patients with mitral incompetence and aberrant coronary arteries
requiring reimplantation. In these cases, the degree of mitral in-
competence was severe, and on assessment it was considered that
mitral function would not improve sufficiently with coronary cor-
TABLE 1. Distribution of anatomic abnormalities in cases
of mitral stenosis and incompetence, as classified by Car-
pentier and colleagues12
Mitral valve abnormality No.
Mitral valve stenosis 15
Type A (normal papillary muscle) 6
Supravalvular ring 4
Leaflet fusion 2
Type B (Abnormal papillary muscle) 9
Parachute 6
Papillary muscle abnormality 3
Mitral valve incompetence 30
Type I (normal leaflet motion) 27
Cleft anterior leaflet 13
Annular dilatation 11
Leaflet defect 3
Type II (leaflet prolapse) 1
Elongated chordae 1
Type III (restricted leaflet motion) 2
Type A (normal papillary muscle) 0
Type B (abnormal papillary muscle) 2
Papillary muscle hypoplasia 2
TABLE 2. Repair strategies used in the reconstruction of
mitral valve anomalies at first operative intervention in this
series
Repair strategy No. %
Stenosis
Papillary muscle split 9 60
Resection of supravalvular ring 7 46.6
Commissurotomy 5 33.3
Repair of chordae 2 13.3
Wooler-Kay annuloplasty 1 6.6
Annuloplasty ring 1 6.6
Incompetence
Cleft suture 14 46.6
Posterior annuloplasty 5 16.6
Wooler-Kay annuloplasty 6 20
De Vega anuloplasty 5 16.6
Papillary muscle split 4 13.3
Annuloplasty ring 3 10
Leaflet replacement with autologous pericardium 1 3.3
Leaflet resection 1 3.3
Paneth annuloplasty 1 3.3rection alone.
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Children with increasing symptoms (lethargy, fatigue, noted diminu-
tion in exercise tolerance), evidence of rising pulmonary pressures
(half systemic or greater), or increasing left ventricular chamber size
on surveillance echocardiography were considered for surgical inter-
vention. Where possible, associated congenital cardiac defects such as
patent ductus arteriosus or aortic coarctation were addressed first, and
mitral surgery was delayed. The surgical aim was to restore a widely
patent and competent pathway between the inflow and outflow tracts
of the left ventricle. More recent surgical management included eval-
uation of the mitral valve anomaly with intraoperative transesopha-
geal echocardiography, although this constituted only 3 cases of the
series, none with reoperation. Surgery was performed with aortobi-
caval cannulation and cardiopulmonary bypass, with most group 1
patients (23/30) kept at moderate systemic hypothermia (28°C). Pro-
found hypothermia (18°C) was more frequently used in more com-
plex cases (11/15). Circulatory arrest was not used. The mitral valve
was approached through a left atriotomy posterior to the interatrial
groove. Initially, antegrade cold crystalloid cardioplegia was used, but
the practice evolved to antegrade cold potassium-enriched blood
cardioplegia after 1993. The annulus, leaflets, chordae tendineae, and
papillary muscles were carefully inspected to determine the precise
anatomy of the lesion and to plan the procedure. The mitral orifice
size was measured with a Hagar dilator and compared with the
expected mean normal valve diameter for the mitral valve relative to
body surface area (BSA).13 Annular dilatation producing central valve
incompetence was treated by means of reduction annuloplasty tech-
niques. The posterior leaflet was advanced forward to coapt with the
anterior leaflet, according to the principles of Carpentier. 6 The annular
orifice was downsized to the size predicted by BSA. The choice of
annuloplasty performed was determined by the BSA of the child. A
Wooler-Kay annuloplasty was performed on the very young with
BSA less than 0.5m2. The Wooler-Kay annuloplasty consists of single
mattress sutures reinforced with pledgets at the commissural sites. 14
Other suture plication techniques were used between 0.5 and 0.9m2.
In a Paneth annuloplasty, a double-armed, pledgeted 2-0 polypro-
pylene suture was placed at the margin of the central fibrous body,
TABLE 3. Demographic, operative, and outcome data from
atrial septal defect or patent ductus arteriosus) and group
Total (No.)
Male (No.)
Age (mo, mean  SD)
Mean preoperative pulmonary pressure (mm Hg, mean  SD)
Mitral stenosis (No.)
In-hospital death (No.)
Late death (No.)
Reoperation (No.)
Cardiopulmonary bypass (min, mean  SD)
Crossclamp (min, mean  SD)
Weight (kg, mean  SD)
Intensive care unit stay (d, mean  SD)
In-patient stay (d, mean  SD)
Group 2 had a significantly higher hospital mortality and required surgerysutured circumferentially around the annulus in 2- to 3-mm steps to
68 The Journal of Thoracic and Cardiovascular Surgery ● July 2the posterior portion of the annulus, and tied over a second pledget. A
second suture was placed on the opposite side of the annulus.15 The
De Vega annuloplasty was performed in two sections with a contin-
uous suture that involved the entire ventricular free ventricular wall,
with pledgets placed at both commissures.16 Complete annuloplasty
rings were not used. A posterior annuloplasty ring was used in
children with a mean BSA greater than 0.9m2.13 An incomplete
annuloplasty ring was used in 4 cases. In 1 case, a Puig-Massana ring
was used, whereas the Mitral Repair System (MRS; Kohler Chemie,
Alsbach-Hahnlein, Germany) ring was used in the other 3. Anticoag-
ulation was not used in any patient after mitral reconstruction. Split-
ting and fenestration of interchordal spaces were performed in cases
with single papillary muscle. Chordal transfer techniques or artificial
replacement were not used. The techniques used in the repair of mitral
disease varied according to morphology (Table 2). Inhaled nitric
oxide has been routinely available in our unit since 1992. The 2
patients with anomalous left coronary artery underwent direct aortic
reimplantation of the artery and a modified De Vega mitral annulo-
plasty. When valve replacement is required, it has been our current
practice to use a St Jude Medical device (St Jude Medical, Inc,
Minneapolis, Minn). To date, the youngest patient at implantation has
been a 2 year old and a total of three devices have been placed in our
unit during this period. Extracorporeal membrane oxygenation was
not used to salvage any patient in this series.
Data Analysis
Statistical analysis was performed with SPSS version 12.0 soft-
ware (SPSS Inc, Chicago, Ill). Actuarial analysis of events was
made with the Kaplan-Meier method (Figure 1). Comparisons
between groups with nominal data were made with a 2 test, and
those of parametric data with a Student t test.
Results
Mortality
The in-hospital (30-day) mortality in group 1 was 3.3%
(1/30). Group 2 had a significantly higher in-hospital mor-
ients in group 1 (isolated mitral disease with or with out
itral anomaly with intracardiac disease or LVOTO)
Group 1 Group 2 P value
30 15 —
13 9 .292
62.3 52.9 16.1 14.1 .002
35 16.4 39 16.6 .526
9 6 .502
1 4 .019
1 0 .475
4 3 .561
54.8  24.6 80.1 46.1 .02
26 14.1 30 13 .405
18.2 12.7 8.4 3.8 .01
4.4 4.2 8.5  7.63 .06
12.15  7.33 14.4 9.3 .423
significantly younger age.pat
2 (mtality, with 4 deaths (26.6%, 21  5.5125, P  .019). The
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Ddeath in group 1 was that of a 9-month-old boy with mitral
regurgitation, a single papillary muscle, and pulmonary
hypertension. He died of a tachyarrhythmia (junctional ec-
topic tachycardia) on postoperative day 1. The 4 deaths in
group 2 were those of 2 boys and 2 girls: a 20-month-old
boy with a preoperative mean pulmonary pressure of 53 mm
Hg who had a postoperative hypertensive crisis, a 41-
month-old girl with complex LVOTO and mitral incompe-
tence who underwent a Paneth type repair and aortic val-
votomy and died when brought back to theatre the next day
for further management of residual LVOTO, a 2-month-old
boy with anomalous left coronary artery and ischemic mitral
incompetence who underwent reimplantation of the left
coronary artery and a De Vega repair of the incompetent
valve and died as a result of low output syndrome on day 5
while being weaned from ventilation, and a 7-month-old
girl who underwent a commissurotomy and papillary mus-
cle split for a parachute mitral valve and also VSD closure
and died as a result of a tachyarrhythmia (junctional ectopic
tachycardia) at postoperative 2 days. In-hospital mortality
was not significantly associated with type of mitral pathol-
ogy, preoperative pulmonary pressures, extracorporeal cir-
culation duration, or type of cardioplegia used. Although
there was a significant difference in age and weight between
groups 1 and 2 (Table 3), analysis of age (P  .132) and
weight (P  .097) separately from anatomic factors dis-
cerned no significant relationship between age and risk of
30-day mortality, although 3 of the in-hospital deaths were
among the 18 children younger than 1 year at the time of
surgery (16.6%). There were no early deaths (30 days to 1
year). The only late death (1 year) was that of a female
patient 13 months after initial mitral repair who required
reoperation for a second reconstruction and died of a tachy-
arrhythmia associated with a postoperative low output syn-
drome. This patient had mitral stenosis as the dominant
pathology. In group 1, the 15-year survival was 93%, versus
73% for group 2. The overall population survival at 15 years
was 86.5%.
Morbidity
Nonfatal complications included the case of a patient who
was brought back to the operating room for management of
postoperative bleeding. One patient required a permanent
pacemaker for complete heart block, and another had a
chylothorax develop. Seven patients (4 with mitral incom-
petence, 3 with stenosis) required 9 revision surgical pro-
cedures. The first repair was performed within 30 days of
the primary procedure in 3 cases. These three cases predated
the availability of intraoperative transesophageal echocar-
diography in out unit. In 2 cases the dominant mitral pa-
thology was incompetence, and in 1, stenosis. In the mitral
stenosis case and one of the incompetence cases, there was
significant postoperative mitral regurgitation requiring rein-
The Journal of Thoractervention. In this incompetence case, further repair was
successful; in the mitral stenosis case, however, valve re-
placement was required. The third patient was brought back
on day 1, not to address mitral pathology but rather to
further address LVOTO (subaortic stenosis), which had
become more significant in the presence of a competent
mitral valve. Other required reoperations were performed
within 1 year in 1 case and between 1 and 4 years in the
remaining 3 cases. All 9 procedures were performed within
4 years of the primary mitral repair. There was no signifi-
cant difference between groups 1 and 2 in reoperation rate
(Table 3). Patient age at operation, type of cardioplegia, and
dominant type of mitral pathology were not associated with
failure of repair. Two mitral valve replacements were re-
quired at reoperation, 1 in a patient with stenosis and 1 in a
patient with incompetence (25-mm CarboMedics valve; and
19-mm St Jude Medical valve). In group 1, the 10-year
freedom from reoperation was 82.9% versus 72.7% for
group 2. The overall freedom from reoperation at 15 years
was 81.7%. There were no detected incidences of thrombo-
embolism, anticoagulation-related hemorrhage, endocardi-
tis, or sudden death. The event-free rate at 15 years was
73.5%.
Previous AVSD Repair
Separate analysis of the group undergoing mitral repair after
a previous AVSD reconstruction was performed. This group
consisted of 7 patients with a mean age of 62 months. There
were three boys. There were no deaths and only 1 reopera-
tion. One patient was in group 2 with subaortic stenosis. The
patient with reoperation underwent two further procedures
and ultimately a mitral valve replacement. The 10-year
survival therefore was 100%, with a freedom from reopera-
tion of 85.7%. Among the children without previous AVSD
surgery, there were 38 patients with a mean age of 44.7
months (19 boys). This latter group had a 10-year survival
of 83.9% and a freedom from reoperation of 81.2%.
Discussion
The results of mitral reconstruction in children with ac-
quired mitral incompetence are excellent, with a reported
10-year survival of 90%.17 However, congenital mitral
anomalies represent a more complex population with a high
prevalence of associated cardiac anomalies. During the 18-
year experience from a single operator presented here, mi-
tral valve reconstruction techniques learned from adult prac-
tice were successfully applied to the pediatric setting. Mitral
valve repair was performed in all cases at the first surgical
intervention, yielding survival and freedom from reopera-
tion comparable with those of other published series (Ta-
ble 4).
Mitral valve repair has many advantages relative to re-
placement. Prosthetic replacement–associated problems
ic and Cardiovascular Surgery ● Volume 130, Number 1 69
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Dwith hemolysis, perivalvular leak, valve thrombosis, throm-
boembolism, and endocarditis are avoided or minimized.
Repair conserves the chordae and subvalvular apparatus,
preserving normal left ventricular geometry and function.18
Conservation of the normal geometry preserves left ventric-
ular function and leads to survival benefits in the long term.3
Valve replacement is difficult in infants younger than 1
year, as was the case in 40% of our series population. This
is because of size mismatch between the prosthesis and
annulus, which interferes with cardiac function, distorting
the geometry of the cavity and frequently obstructing the
left ventricular outflow tract.19 This may be minimized with
supra-annular placement of the prosthesis, but the problem
remains that these very young children will quickly outgrow
the prosthetic valve, requiring reoperation, and the long-
term survivorship has yet to be confirmed. Annular dilation
was the major factor in mitral incompetence in 36.6% of
cases in this series. In these cases, repairs with rigid annu-
loplasty rings were avoided, particularly in infants younger
than 1 year. This was done to avoid interference with valve
annulus growth and the complications of endocarditis and
thromboembolism. In most cases a commissural plication
annuloplasty technique to correct annular dilatation was
used. However, in 4 cases annuloplasty rings were required.
Annuloplasty rings are associated with interference in the
TABLE 4. Demographic, operative, and outcome data fro
associated intracardiac disease at the time of mitral valve
Reference
Period
(y)
Age
<1 y
Current series 18 40%
McCarthy et al,1 1996 10 43.4% 
Serraf et al,2 2000 18 44% 
Prifti et al,4 2002 10 27% 
Stellin et al,5 1988 14 16.6% 
Chauvaud, et al,6 1998 25 —* 
Zias et al,7 1998 7 —* 
Aharon et al,8 1994 11 24%  2 y 
Stellin et al,9 2000 12 11.7% 
Uva et al,10 1995 13 100% 
Yoshimura et al,11 1999 20 —* 
Caldarone et al,19 2001 17 38.8% 
Eble et al,22 2003 18 20.7% 
Kadoba et al,23 1990 14 100% 
Lorier et al,28 2001 23 —* 
Moran et al,29 2000 11 —* 
Okita et al,30 1988 17 12%  2 y 
Erez et al,31 2003 20 —* 
Patients with associated intracardiac disease (group 2) were significantly
stay. E, Endocarditis; VT, valve thrombosis; SCD, sudden cardiac death; Tnormal cardiac wall motion and function, but incomplete
70 The Journal of Thoracic and Cardiovascular Surgery ● July 2rather than complete rings were used to minimize any
restriction of movement of the anterior mitral leaflet and
trigone area.20 All 4 patients survived, and none have yet
required revision surgery. The management of anticoagula-
tion in a pediatric population is challenging for child, par-
ent, and physician. An incidence of serious hemorrhage of
9% and a 12% incidence of thromboembolic events were
reported in a review of children anticoagulated with warfa-
rin after cardiac valve replacement.21 This is avoided with
mitral repair, which obviates the need for anticoagulation.
In considering alternatives to repair, data regarding mor-
tality, freedom from reoperation, and event-free survival are
essential (Table 4). Most series report significant mortality
from mitral valve replacement, with death or transplant rates
of 36% when mechanical valves were used exclusively22
and 47% to 56% from populations of mixed bioprosthesis
and mechanical valves23,24 where the 5-year survival was
reported as 43%.23 In contrast, one Japanese center has
reported no in-hospital mortality for mechanical valve re-
placement in children and a 10-year survival of 90.3%.11
However, the group’s freedom from reoperation at 10 years
was similar to other studies at 66% to 67.3%.11,22 The
15-year freedom from reoperation rate in this series of
mitral valve reconstructions, 81.7%, compares favorably
with the rates after valve replacement. Although biologic
atients grouped by presence or absence of significant
gery
Mean
age (y)
Median
age (y)
Valve
repair
Valve
replacement
2.16 45 0
3.2 23 0
1.5 72 0
5.2 94 0
6 26 4
5.7 138 7
6.0 26 0
4.9 79 0
5.9 34 0
0.55 19 1
3.6 36 20
1.42 0 139
5.0 0 53
0.58 0 25
4.6 21 0
2.8 37 9
5.5 66 0
8.1 0 90
ger and smaller and had higher early mortality and longer intensive care
omboembolic event; CVA, cerebrovascular accident. *Data not available.m p
sur
younvalve replacements have been used, porcine mitral biopros-
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Dtheses in the pediatric population are associated with accel-
erated tissue calcification and failure.25 This poorer perfor-
mance with biologic valves is also consistent with reports of
high early mortality and 5-year failure from adult use of
mitral homograft valves.26 Gulbins and colleagues,27 again
in an adult population, report that 3 of 8 complete ho-
mografts required replacement within 3 years of surgery.
Among the published articles reviewed, only Chauvaud and
associates6 commented on event-free survival, reporting a
69% event-free rate at 10 years.
Few reports on congenital mitral valve anomaly repair
have identified predictors of poor outcome. This may reflect
the small numbers generally found in such series. The major
factor associated with increased in-hospital mortality in this
series was the presence of associated significant intracardiac
disease. This group was also found to be significantly
younger and hence lighter at the time of operation, but
analysis of age or weight separately from the anatomic
division between groups 1 and 2 showed no significant
relationship between age or weight and outcomes. The
cardiopulmonary bypass time was longer in the groups with
complex anatomic pathology, which could be explained by
the time required to address the associated pathology. How-
ever, crossclamp time was not significantly longer. The
longer cardiopulmonary bypass time is more likely to reflect
In-hospital
death
Late
death Reoperation Survival
5 1 7 86.5% at 15 y
3 2 3 77.4% at 7 y
9 8 24 69.6% at 15 y
8 9 6 89.2% at 5 y
5 1 3 —*
7 10 21 Repair 88% at 10 y,
replacement 51% at
1 0 4 —*
3 3 10 82% at 5 y
0 1 3 96.8% at 12 y
0 1 11 94% at 7 y
2 2 6 Repair 87.2% at 10 y,
replacement 90.3% a
25 4 32 74% at 10 y
6 8 18 —*
9 5 9 43% at 5 y
2 0 4 —*
1 4 * Repair 92.6% at 10 y,
replacement 85.7% a
1 4 * 88.4% at 17 y
17 4 12 70.5% at 10 ythe practice of using profound hypothermia in patients with
The Journal of Thoracmore complex problems. Other groups have also observed
poorer survival in cases with associated cardiac anoma-
lies.2,4 The associated intracardiac anomalies identified in
this series as high risk consisted of concurrent repair of
VSD, LVOTO, and anomalous coronary artery. The in-
creased risk may be due to more complex anatomy,
LVOTO, VSD, and the presence of impaired ventricular
function, which struggles postoperatively with corrected
circulatory flow. In considering whether any associated
intracardiac disease should be addressed before mitral valve
repair, the combined mortality of two separate procedures
would have to be superior, and Serraf and coworkers2
reported a better outcome when all anomalies were repaired
in a single stage rather than in a two-stage fashion. In
studies of mitral valve replacement, the outcome of patients
with significant associated cardiac disease has not been
analyzed separately, so there are no comparative data en-
abling a true analysis of whether this group would have
superior outcomes with valve replacement at first attempt.
This would seem unlikely, however, because the placement
of a mechanical valve is unlikely to offer benefits relative to
repair in a situation of poor left ventricular function or to
reduce the operative times significantly. Other reported pre-
dictors of poor outcome include age younger than 1 year,
which was not statistically significant in this study, ham-
Freedom from reoperation Adverse events
81.7% at 15 y 0
84.1% at 7 y 0
70.8% at 15 y 2 E, 2 VT
76.3% at 5 y 0
—* 1 SCD
Repair 67.7% at 15 y,
replacement —*
2 TE, 1 CVA, 1 E, 1 SCD
—* 0
83% at 8 y 1 TE
85.9% at 12 y 0
58% at 7 y 2 VT
Repair 72.7% at 10 y,
replacement 67.3% at 10 y
3 VT, 1 valve
dysfunction
81% at 5 y 8 E, 4 VT, 3 CVA
66% at 10 y 6 VT, 1 CVA
45% at 3 y 0
46 % at 10 y 0
Repair 78.5% at 9 y,
replacement 85.7% at 9 y
1 E
86% at 17 y 0
—* 6 TE, 9 bleeding events10 y
t 10 y
t 10 ymock mitral valve, and cardiomegaly.2,4 No significant fac-
ic and Cardiovascular Surgery ● Volume 130, Number 1 71
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reoperation, although mitral stenosis is reported to have a
higher reoperation requirement.4,9
The in-hospital death rate reported in this study is higher
than in some recent reports (Table 4). We believe this is
related to the high proportion of cases with associated
significant intracardiac disease (33.3%), which we have
identified as a mortality risk factor. In addition, there was a
large proportion of patients younger than 1 year (40%) and
with stenosis (33.3%) which, although not statistically sig-
nificant factors in this study, are factors that have been
associated with poorer outcome in other studies.4 This series
covers a longer period then many contemporary reports, and
differences in mortality compared with shorter recent stud-
ies may reflect improvements in preoperative optimization,
intraoperative cardiac protection, cardiopulmonary bypass
management, and postoperative intensive care management,
especially in relation to the pharmacologic management of
pulmonary hypertension.
Conclusion
This review covers a significant follow-up period, and only
a few published reports cover similar periods.6,11,28 Higher
mortality with repair was observed when associated with
significant intracardiac disease. Whether this group would
benefit from mitral valve replacement at the first attempt has
yet to be determined. Every effort should be made to pre-
serve the natural valve, even when very dysplastic, by
reconstructive techniques. Our experience with mitral valve
repair rather than replacement as the first surgical interven-
tion has proved it to be a reliable tool and satisfactory
alternative to replacement of the valve, with no other events
other than reoperation. Later valve replacement is still pos-
Figure 1. Kaplan-Meier curve shows survivals and event-free
rates for 18-year period. Cumulative reoperation rates (numbers in
parentheses) are also shown.sible, but it is at least postponed, preferably until adulthood,
72 The Journal of Thoracic and Cardiovascular Surgery ● July 2when the problems of mechanical valve size and growth are
less significant and anticoagulation can be managed
independently.
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